DDX41 and neoplasm: As several anti-CCR2 Abs are under development (Table 3), it would be of interest whether anti-tumor efficacy links to their cell depleting property, and whether the depleting effect of anti-CCR2 Abs could be enhanced by antibody drug conjugation via antibody-guided delivery of cytotoxic drugs.